The drugs don’t work for consumer goods giant Reckitt Benckiser and today UBS analysts agreed. Back in October, the Nurofen, Dettol and Durex owner said that its pharmaceutical division is under strategic review and the City expects a £1.1 billion sale is the most likely option. But today UBS said the current valuation for the group is “much greater” than is “likely to be released” if they sell it.
Help employers find you! Check out all the jobs and post your resume.
